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Plasmodium falciparum gametocyte kinetics and infectivity may differ between chronic and
incident infections. In the current study, we assess parasite kinetics and infectivity to mos-
quitoes among children (aged 5–10 years) from Burkina Faso with (a) incident infections
following parasite clearance (n= 48) and (b) chronic asymptomatic infections (n= 60). In
the incident infection cohort, 92% (44/48) of children develop symptoms within 35 days,
compared to 23% (14/60) in the chronic cohort. All individuals with chronic infection carried
gametocytes or developed them during follow-up, whereas only 35% (17/48) in the incident
cohort produce gametocytes before becoming symptomatic and receiving treatment. Parasite
multiplication rate (PMR) and the relative abundance of ap2-g and gexp-5 transcripts are
positively associated with gametocyte production. Antibody responses are higher and PMR
lower in chronic infections. The presence of symptoms and sexual stage immune responses
are associated with reductions in gametocyte infectivity to mosquitoes. We observe that
most incident infections require treatment before the density of mature gametocytes is
sufficient to infect mosquitoes. In contrast, chronic, asymptomatic infections represent a
significant source of mosquito infections. Our observations support the notion that malaria
transmission reduction may be expedited by enhanced case management, involving both
symptom-screening and infection detection.
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The epidemiology of P. falciparum transmission stages,gametocytes, is poorly understood. Molecular diagnosticsshow that low-density gametocyte carriage is highly pre-
valent in endemic populations1 and that many low-density
infections are infectious to mosquitoes2, explaining observations
from the 1950s that gametocyte-free individuals (as determined
by microscopy) frequently infected mosquitoes3. Few assessments
of the population infectious reservoir of malaria parasites have
been undertaken4,5, particularly with tools capable of detecting
low parasite and gametocyte densities6,7. Fewer still have been
able to assess the association of infectivity with factors other
than parasite density, despite clear evidence that gametocyte
maturity8,9, intrinsic parasite factors10,11, human genetic
factors12, and human clinical and immune responses13–15 can
have significant influence on the effectiveness of parasite
transmission.
Higher densities of pathogenic asexual stage malaria parasites
are commonly associated with the presentation of symptoms16.
Because gametocytes develop from asexual parasites, individuals
with clinical malaria and higher parasite densities may have more
gametocytes and be more likely to infect mosquitoes17,18. On the
other hand, the long maturation process of gametocytes may
result in higher gametocyte densities in infections of longer
duration that are often asymptomatic6,19. These uncertainties
have added to the ongoing debate over the importance of
asymptomatic infections for malaria transmission19–21. To truly
understand the interaction of symptomatic status and the tem-
poral dynamics of malaria infection, longitudinal assessments are
required that can determine whether infected individuals living in
malaria-endemic areas are infectious to mosquitoes before
symptoms arise or before malaria infections are detectable with
standard diagnostics. Such longitudinal studies can also pro-
spectively assess how gametocyte production is influenced by
infection characteristics such as parasite multiplication rates22,
clinical symptoms, duration of infection and complexity of
infection23.
In the present longitudinal study, we aimed to describe changes
in asexual and sexual parasite density and infectiousness at two
moments of the parasite’s natural history: immediately after
blood-stage infection establishment, and during the chronic phase
of the infection. We hypothesized that a large proportion of
incident infections would develop into chronic asymptomatic
infections that are highly infectious to mosquitoes and that both
host and parasite factors influence gametocyte production and
infectivity. To test these hypotheses, we recruited two cohorts of
school children from Balonghin, Burkina Faso. In the first cohort,
aiming to characterize incident infection dynamics, individuals
without infections were monitored weekly by PCR for up to
6 months to detect new infections at their onset. In the second
cohort, aiming to characterize chronic asymptomatic infections,
individuals were enroled for monthly monitoring, and were
classified as having chronic and asymptomatic infection when
parasites were detected on consecutive visits by PCR in the
absence of symptoms. Blood samples were taken to measure total
parasite density, complexity of infection, parasite multiplication
rates over 48-h intervals, asexual and sexual stage anti-malarial
antibodies, and male and female gametocyte densities. Pro-
spective gametocyte production was estimated by determining the
ratio of gametocytes present at day 14 of follow-up to the density
of ring-stage parasites at enrolment. The abundance of P. falci-
parum Apetala2-G (ap2-g; PF3D7_1222600) and Gametocyte
exported protein 5 (gexp-5; PF3D7_0936600) gene transcripts
were assessed as proxies of sexual conversion. Infectivity to
mosquitoes was determined upon detection of incident or chronic
asymptomatic infections, and at multiple time points during
follow-up.
Results
Parasite and gametocyte kinetics differ between incident and
chronic infections. A total of 253 individuals were screened for
participation in the incident infection cohort; 80 were confirmed
Plasmodium negative by nested PCR (nPCR) that was conducted
immediately on-site, and followed up weekly to monitor for
infection (Table 1). Fifty-two individuals became Plasmodium
positive, prompting their full enrolment into the cohort. The
median observation period from nPCR confirmation of parasite
negativity to infection detection and enrolment (day 0) was
27 days (interquartile range [IQR] 20–41). Four individuals were
subsequently dropped from this analysis after quantitative PCR
(qPCR), performed upon study completion, showed that Plas-
modium parasites were present at time points more than 2 weeks
prior to their detection by nPCR, leaving 48 individuals in the
incident infection cohort. For the chronic infection cohort, 228
individuals were screened and 60 asymptomatic, parasite positive
individuals were enroled. At enrolment, all participants in this
cohort had been parasite positive for approximately 1 month
(median 28.5 days [IQR 28–38.5]). Screening and follow-up time
points are shown for all individuals in Supplementary Fig. 1.
Blood samples were taken from individuals with confirmed
incident or chronic infection at enrolment (day 0), then daily for
1 week, and weekly until day 35 or the presentation of malaria
symptoms (Fig. 1). Infectivity to mosquitoes was determined at
day 0, 14 and 35, or at the final visit if this preceded day 35 due to
the presentation of symptoms.
At day 0, total parasite densities by qPCR were similar for
chronic and incident infections (Table 1). Average parasite density
trajectories for individuals in both cohorts are presented in Fig. 2A
(data for individual participants is shown in Supplementary Fig. 2).
During follow-up, median peak parasite density was higher in
incident infections (p= 0.0001). At day 0, gametocytes were
detected by qRT-PCR in 6% (3/48) of individuals with incident
infections and 97% (58/60) of individuals with chronic infections.
Only 35% (17/48) of individuals in the incident cohort developed
detectable gametocytaemia during follow-up compared to 100%
(60/60) of chronic infections. In both cohorts, there was
considerable variation in gametocyte densities between individuals
(Fig. 3A, B), but the median gametocyte density among positives at
any time point (p < 0.0001) and the median peak gametocyte
density were both significantly higher in chronic infections (p <
0.0001). Combining both cohorts, the association of gametocyte
densities at day 14 with total parasite densities at day 0 (Spearman
rho 0.48 p= 0.0001) (Fig. 3C) was significantly stronger than
between gametocytes and total parasites at day 14 (Spearman rho
−0.19 p= 0.1292) (Supplementary Fig. 3B). The intensity of
sampling in the first week of follow-up allowed for assessments of
parasite multiplication rate (PMR). PMR was calculated as the
change in total parasite density between measures at 48-h intervals,
giving multiple PMR observations per individual (Fig. 2B). PMR
values varied widely within and between individuals. Geometric
mean PMR was higher in individuals with incident infection (6.70,
95% CI [4.76–9.42]) compared to those with chronic infection
(1.08 [0.90, 1.28]) (p < 0.0001); age and sex had no significant effect
on this association. There was no evidence that PMR changed over
time in the first week of intensive follow-up (incident, p= 0.423;
chronic, p= 0.338). In the same period, gametocyte densities
within individuals remained stable; the standard deviation (SD) of
48 hourly changes in gametocyte density was significantly lower
than the SD of PMR in the same individuals (p < 0.0001)
(Supplementary Fig. 3A). Among chronic infections, gametocyte
densities decreased in the first week of observation (mean change
over 48-h intervals= 0.87 [95% CI 0.77–0.97]).
Gametocyte sex ratio (the percentage of total gametocytes that
were male) was significantly higher in chronic infections (median
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38.1%) than incident infections (20.4%) (p= 0.027) (Supplemen-
tary Fig. 4). There was no association between haemoglobin (Hb)
level at day 0 and gametocyte sex ratio at day 14 for participants
with incident infections (p= 0.482), chronic asymptomatic
infections (p= 0.620), or chronic infections that became
symptomatic (p= 0.116).
Infectivity to mosquitoes is higher among chronic infections.
212 mosquito feeding assays were conducted over the course of
the studies, with 52 assays in the incident cohort and 160 assays
in the chronic cohort. Details of mosquito infection experiments
are presented in Supplementary Table 3. The lower number of
assays performed on individuals with incident infection reflects
the earlier symptom presentation in this cohort. As demonstrated
previously, there was a positive association between gametocyte
density and mosquito infection rate (Fig. 4A, Spearman rho 0.51,
p < 0.0001)24. Given that gametocyte densities were variable
between and stable within individuals it is unsurprising that there
was heterogeneity in infectivity between individuals (p < 0.0001).
After adjusting for gametocyte density, there was still strong
evidence for heterogeneity in infectivity between individuals (p <
0.0001), indicating that factors other than gametocyte density are
also relevant in explaining transmission potential of infected
individuals.
2/34 individuals with incident infection were infectious to
mosquitoes on at least one occasion, resulting in 0.1% (5/3403) of
mosquitoes becoming infected. By comparison, 28/60 individuals
with chronic infection were infectious to mosquitoes on at least
one occasion, infecting 4.5% (554/12,405) of mosquitoes
(Supplementary Table 3). Gametocyte densities were generally
higher in chronic infections, but after adjustment for gametocyte
density the risk of mosquito infection for individuals in the
chronic cohort remained higher (risk ratio= 10.44 [95% CI
2.79–39.01], p= 0.0005); this was true even after further adjusting
for the presence of symptoms (risk ratio= 11.17 [95% CI
3.08–40.48], p= 0.0002). During chronic infections, there was
no significant effect of assay timing (days after enrolment) on
infectivity, whether adjusted (p= 0.332) or unadjusted (p=
0.058) for gametocyte density (Fig. 4B). Too few incident
infections gave rise to mosquito infection to allow the same
analysis; the two infectious feeds in this cohort were on days 1
and 16 after enrolment. There was no statistically significant
correlation between total parasite density and infectivity (Spear-
man rho 0.12, p= 0.081), reflecting the observed lack of
correlation between asexual and gametocyte densities. 88% of
infectious individuals had total parasite densities above 50/µL
(between the detection thresholds of expert field microscopy and
standard RDTs25) (Supplementary Fig. 5). All infectious indivi-
duals had parasites above the estimated detection threshold of
standard qualitative PCR (1 parasite/µL)26. There was no
evidence that optimal sex ratios (between 10 and 50% male)
were associated with higher mosquito infection rates (p= 0.634);
the relationship between sex ratio and infectivity is complex, and
has been explored in greater detail elsewhere24.
Complexity of infection is higher in chronic infections and
associated with mosquito infection rates. Targeted deep
sequencing of apical membrane antigen 1 (AMA1) demonstrated
that the majority of cohort participants had clonally complex
infections at the start of intensive follow-up, both for incident
infections (67% [31/46] multi-clonal, median complexity of
infection (COI) = 3 [IQR 1–4]) and chronic infections (93%
[51/55] multi-clonal, median COI = 6 [IQR 5–9]) (Table 1). The
prevalence of multi-clonality (p= 0.001) and COI (p < 0.0001)



















































































































































































































































































































































































































































































































































































































































































































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22573-7 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2443 | https://doi.org/10.1038/s41467-021-22573-7 | www.nature.com/naturecommunications 3
start of follow-up. Among the few incident infections that
remained asymptomatic, 33% (2/6) and 100% (2/2) were multi-
clonal at days 14 and 35, respectively. Chronic infections showed
similar complexity throughout follow-up (day 14= 98% multi-
clonal [46/47], median COI = 6 [IQR 4–8], day 35= 95% multi-
clonal [39/41], median COI = 6 [IQR 4–8]). Neither complexity
of infection at the start of follow-up (p= 0.139) nor Hb genotype
(p= 0.914) were associated with PMR in the first week of follow-
up. After controlling for gametocyte density and cohort, com-
pared to those with 3 or fewer clones, those with 4–6 clones at the
day of mosquito feeding were 4.23 [95% CI 1.37–13.10] times
more likely to infect a mosquito, and those with 7 or more clones
were 4.30 [95% CI 1.73–10.71] more likely (p= 0.007).
Symptoms develop rapidly during incident infection and are
associated with reduced infectivity to mosquitoes. Most indi-
viduals with incident infections experienced symptoms prior to
the end of follow-up at day 35 (92%, 44/48), compared to only
23% (14/60) of those with chronic infections. For those who
developed symptoms, the median interval between day 0 and the
onset of symptoms was 4 days (IQR 2–7) for incident infections,
and 11 days (IQR 6–22) for chronic infections. At symptom
presentation, median total parasite densities were 14,382/µL (IQR
2963–45,601) in chronic infections and 10,545/µL (IQR
1077–17,950) in incident infections (p= 0.251). Median game-
tocyte density at symptom presentation was 0/µL (IQR 0–0) in
incident infections, and 5.3/µL (0.5–23.5) for chronic infections
(p= <0.0001). In chronic infections that became symptomatic,
total parasite densities increased during follow-up (average
increase 6.0% per day [CI 0.08–15.2, p= 0.023, n= 14]), whereas
for those that remained asymptomatic total parasite density
decreased (average decrease 1.7% per day [CI 0.6–2.7%, p=
0.002, n= 46; p value for difference <0.0001]). In incident
infections that became symptomatic, total parasite densities
increased during follow-up (average increase 73.0% per day [CI
58.3–88.0, p= <0.0001, n= 44]), whereas for those that remained
asymptomatic total parasite densities remained level (0.2%
decrease per day [CI −6.3–6.3%, p= 0.964, n= 4; p value for
difference <0.0001]). PMR was higher in incident infections
leading to symptoms than incident infections that remained
asymptomatic (p= 0.001) or chronic infections with (p < 0.001)
or without symptoms (p < 0.001). There was no evidence that
PMR was different between incident infections that remained
asymptomatic, chronic infections that remained asymptomatic,
and chronic infections that became symptomatic (p= 0.301).
When mosquito feeding assays were conducted concurrently
with the presentation of symptoms (25/212) infectivity was
signficantly decreased (risk ratio= 0.30 [95% CI 0.13–0.71], p=
0.0061); this was also the case after incident infections were
excluded from the analysis (risk ratio= 0.26 [95% CI 0.11–0.65],
p= 0.004).
Factors associated with gametocyte production. PMR and
parasite density at enrolment (day 0) were independently posi-
tively associated with day 14 gametocyte density, whilst game-
tocyte densities were lower among individuals with incident
infection and among older individuals (Table 2). The ratio of
gametocyte density on day 14 to ring-stage parasite density on
day 0 (i.e. the proportion of baseline asexual parasites that sub-
sequently produced gametocytes) was significantly associated
with the ratio of ap2-g transcript copy number to ring-stage
parasite density on day 0 (i.e. the relative abundance of ap2-g)
(Spearman rho 0.42, p= 0.0015) (Fig. 5A). This association was
not observed when gametocyte production at day 14 was exam-
ined in relation to ap2-g production 6–8 days prior (Spearman
rho= 0.04, p= 0.780), an interval that is too short to allow
gametocyte production27. Relative ap2-g abundance on day 0 was
significantly higher in chronic infections than in incident infec-
tions (p < 0.0001) (Fig. 5C). An independent marker of early
sexual stage development, gexp-5, which is detectable in the cell
cytoplasm within 14 h of gametocyte formation28, was strongly
associated with gametocyte production (Spearman correlation
coefficient 0.70, p= <0.0001) (Fig. 5B), and was significantly
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Fig. 1 Illustrative sampling schemes for individuals in the incident and chronic cohorts. Tick marks represent days and weeks, and sampling/screening
time points are shown as circles. Positive (+) and negative (–) symbols inside circles indicate parasite status, as determined by the indicated assays. A In
the incident infection cohort individuals were screened to confirm parasite negativity by microscopy, presumptively treated for sub-patent infection (light
pink circle), and screened 3 weeks later with qualitative nested polymerase chain reaction-based on detection of Plasmodium specific 18s ribosomal DNA
(nPCR) (black circle) to confirm the absence of sub-patent infection. They were then screened weekly with nPCR (white circles) until the onset of an
infection. Intensive follow-up (grey circles) proceeded every day for 1 week, and weekly until day 35 after parasite detection. Study participants were
closely monitored for the development of malaria symptoms. Participants were treated with artemether-lumefantrine upon the detection of symptoms or
35 days after initial detection of infection: whichever came first. B Individuals in the chronic infection cohort were screened monthly with nPCR to confirm
chronic infection (blue circles), defined as two sequential visits with confirmed parasitaemia without any symptoms of malaria disease. Intensive follow-up
proceeding from confirmation of chronic infection (grey circles) was as for incident infections. Participants were treated with artemether-lumefantrine upon
the detection of symptoms or at day 35 of follow-up: whichever came first. Mosquito feeding (indicated with mosquito symbols) was conducted in both
cohorts at the onset of intensive sampling (day 0) and at day 14 and 35 in the absence of symptoms. Mosquito feeding assays were additionally conducted
on the day of symptom detection.
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ap2-g and gexp-5 transcript abundance were correlated (Spear-
man rho 0.55, p= <0.0001). The associations of ap2-g and gexp-5
transcript abundance with gametocyte production remained
highly significant after adjustment for gametocyte density at the
time of measurement (p < 0.0001).
Antibody responses in relation to symptoms, parasite kinetics
and mosquito infection rates. The magnitude of antibody
responses specific to 14 P. falciparum antigens was determined at
enrolment for incident infections (n= 48) and chronic infections
(n= 51). Antibody levels were higher in samples collected from
individuals with chronic infections (p < 0.001 for all 14 antigens).
Baseline antibody levels were significantly higher in individuals
who remained asymptomatic for MSP2-ch150 (p= 0.036) in
incident infections, and EBA-181 (p= 0.042) and GLURP-R2
(p= 0.032) in chronic infections (Fig. 6, Supplementary Table 1).
Time to symptoms was not significantly longer in individuals
with high antibody responses to pre-erythrocytic and asexual
stage antigens in either the chronic cohort (p= 0.180) or the
incident cohort (p= 0.203). In incident infections, antibody levels
were negatively associated with PMR for EBA140 (p < 0.001),
EBA-181 (p= 0.037), and PfAMA-1 (p= 0.030). Among indivi-
duals with chronic infections, antibody levels had no apparent
association with mean PMR (Supplementary Table 2). In the
chronic cohort infectivity was 65% (95% CI 21–85) lower for a
10-fold increase in anti-Pfs48/45 median fluorescence intensity
(MFI) after adjustment for gametocyte density (p= 0.011); fur-
ther adjusting for asexual immune responses infectivity was 48%
(95% CI 5–81) lower for a 10-fold increase in anti-Pfs48/
45 antibody response (p= 0.033). For Pfs230, infectivity was 64%
(95% CI 34–80) lower for a 10-fold increase in MFI with
adjustment for gametocyte density (p= 0.001), but this reduction
was not significant after adjustment for asexual immune
responses.
Discussion
To maximize the impact of malaria control and elimination
programmes, there is a need to identify which individuals are
most important for transmission of Plasmodium to mosquitoes.
Among our study population of school-aged children with
intensively monitored incident and chronic P. falciparum infec-
tions, we observed marked variation in gametocyte production
and mosquito infectivity. Incident infections were characterized
by high parasite multiplication rates and low gametocyte com-
mitment. More than 90% of incident infections resulted in a
detectable fever within 35 days, which in most cases resulted in
treatment before sufficient mature gametocytes were produced to
infect mosquitoes. Gametocyte densities were significantly lower
in incident infections, but even after adjustment for gametocyte
density, the likelihood of transmission remained lower for inci-
dent infections and was further reduced by the presence of
symptoms.
In the current study, children with incident and chronic
infections were examined in detail for parasite kinetics and
infectivity to mosquitoes. The study was conducted in an area of
intense malaria transmission, confirmed by the observation that
65% (52/80) of parasite-free individuals became nPCR positive
within 4 weeks (median participation 27 days [IQR 20–41]).
These incident infections were frequently clonally complex at the
time the infection was first detected in the bloodstream, indi-
cating either co-transmission of multiple P. falciparum strains
during mosquito bites29,30 or repeated inoculations over a short
time-period.
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Fig. 2 Infection trajectory and total parasite multiplication rate. A Total
parasite densities are presented as values relative to the time point of their
first detection. Light blue lines = chronic asymptomatic infection, dark blue
lines = chronic symptomatic infection, light red lines = incident
asymptomatic infection, dark red lines = incident symptomatic infection,
black markers= time of symptom onset. Three individuals became
symptomatic at time points without concurrent parasite density measures.
For these individuals, no black marker was drawn for ‘Day of symptoms’. Full
details of individual parasite and symptom trajectories are in Supplementary
Figs. 1 and 2. B Total parasite multiplication rates (PMR) were calculated as
the change in density between observations over 48-h intervals in the first
7 days of intensive follow-up. Marker colours are as for the lines in (A), with
hollow circles for asymptomatic infection, solid circles for symptomatic
infection, and grey crosses indicating the median PMR for each individual.
The red dashed line at PMR= 1 indicates PMR equality between measures;
values above show PMR values which increased over time, values below the
PMR values which decreased over time. Participants are ordered by the
geometric mean of their PMR observations. 431 measurements of PMR from
92 participants were available (median per person= 6 [IQR 3,6]). Incident
asymptomatic: 13 observations (3 individuals), median observations= 6,
IQR (1,6); Incident symptomatic: 98 observations (31 individuals), median
observations= 3, IQR (2,4); Chronic asymptomatic: 247 observations (44
individuals), median observations= 6, IQR (6,6); chronic symptomatic: 73
observations (14 individuals), median observations= 6, IQR (5,6). Geom.
mean= geometric mean.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22573-7 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2443 | https://doi.org/10.1038/s41467-021-22573-7 | www.nature.com/naturecommunications 5
The rapid infection rates in our study argue against the exis-
tence of sterile immune protection31,32. However, the high pro-
portion of individuals with chronic infections who remained
asymptomatic indicates that there was substantial clinical
immunity in this age-group33. Antibody responses to specific
blood-stage malaria antigens including EBA34, GLURP35 and
MSP236,37 were associated with the ability to control parasite
multiplication and remain symptom-free. In our incident infec-
tion cohort, the majority of individuals failed to control parasite
multiplication and developed malaria symptoms (i.e. fever). Most
incident infections occurred within 2 months (IQR 20–41 days)
after presumptive treatment with dihydroartemisinin-piper-
aquine, when residual piperaquine levels are unlikely to provide
effective prophylaxis38; piperaquine has no known effect on
(developing) gametocytes27,39. In Mali, baseline parasitaemia did
not influence the risk of developing clinical malaria40. It never-
theless remains to be confirmed whether the likelihood of
detecting incident infections by repeated fever screening, that was
high in the current study, is influenced by clearance of infections
before the transmission season. Despite relatively small sample
size, contrary to our expectations, haemoglobin genotype was not
associated with parasite multiplication rates or the likelihood of
remaining free of malaria symptoms upon infection41,42. This
may have been due to our conservative definition of symptomatic
malaria: the protection associated with HbS increases with the
severity of disease43, while in our study individuals were actively
followed and treated immediately upon development of fever.
Our finding that HbS did not affect PMR is in line with a con-
trolled human infection study in Gabon where only the likelihood
of symptoms and not PMR was lower for HbS individuals com-
pared to those with normal haemoglobin44.
Sexual conversion rates, quantified by relative ap2-g and gexp-5
abundance45, were higher in chronic infections than incident
infections. This suggests that although gametocyte production
may start during the first wave of erythrocytic schizogony27,46,
investment in asexual parasite multiplication dominates the
early phase of infection while chronic infections are marked
by higher investment in gametocyte production. This may be
due to chronic inflammation and hence reduced levels of
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Fig. 3 Gametocytes and gametocytogenesis. A Gametocyte density measures from all gametocyte positive individuals (positive at any time point during
follow-up). Light blue hollow markers= chronic asymptomatic infection, dark blue solid markers= chronic symptomatic infection, light red hollow markers=
incident asymptomatic infection, dark red solid markers= incident symptomatic infection, grey crosses indicate the median gametocyte density for each
individual. There were 928 measurements of gametocyte density; the median number of observations per person was 10 (IQR 5–12). For incident infections the
median was 5 observations per person (IQR 3–8.5); for chronic infections the median was 12 (IQR 11–12). Individuals are ranked by median gametocyte density.
B The association of gametocyte density at day 14 and total parasite density at enrolment (day 0). Time points are given as the number of days after enrolment
into the incident or chronic infection cohorts. Line colours are as for the markers in (A), with black markers showing the onset of symptoms. Three individuals
became symptomatic at time points without concurrent parasite density measures. For these individuals, no black marker was drawn for ‘Day of symptoms’. Full
details of individual parasite and symptom trajectories are in Supplementary Figs. 1 and 2. C Total parasite density at enrolment (d0) was positively associated
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Fig. 4 Mosquito infectivity and gametocyte density. A Total gametocyte
density in the different cohort participants in relation to the percentage of
mosquitoes that became infected. Light blue hollow markers= chronic
asymptomatic infection, dark blue solid markers= chronic symptomatic
infection, light red hollow markers= incident asymptomatic infection, dark
red solid markers= incident symptomatic infection. The black line indicates
the shape of the model for the association of gametocyte density and
percentage of mosquitoes infected in mosquito feeding assays for
individuals with chronic infections. This model is described in detail
elsewhere24. Grey shading represents the 95% confidence interval for the
model. This figure is based on 134 observations from chronic asymptomatic
infections, 26 observations from chronic symptomatic infections, 3
observations from incident asymptomatic infections, and 49 observations
from incident symptomatic infections. B The percentage of mosquitoes
infected over time, shown as days since the start of intensive follow-up.
Colours (markers and lines) are as in (A). The size of the data points is
proportional to the log gametocyte density in blood samples taken
concurrent with the mosquito feeding assay. Connecting lines indicate
observations from the same cohort participant.
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Lysophosphatidylcholine (LysoPC) continuously triggering ele-
vated rates of gametocyte production47. There is currently no
in vivo data correlating LysoPC levels to inflammation and
gametocyte production. Following future assessments of the con-
tribution of systemic versus hematopoietic infection to gametocyte
production, the implications of systematic inflammation to
gametocyte commitment should be examined. Our observation
that after adjusting for gametocyte density, the risk of mosquito
infection was lower in incident infections suggests that gameto-
cytes arising in the incident cohort were less mature at the time of
mosquito feeding. The requirement for gametocyte maturation
following release into the circulation would be in line with earlier
in vitro observations that morphologically mature gametocytes
may require several days of maturation to reach peak infectivity48,
and with findings in controlled human infections where infectivity
is only observed several days after gametocyte densities plateau39.
Importantly, many children in the incident infection cohorts
developed symptoms of clinical malaria early upon infection. When
symptoms were detected only 5% (2/42) of individuals had
detectable gametocytes, with densities of 0.06/µL and 0.85/µL.
Among chronic infections, marked variation in gametocyte pro-
duction was observed that was positively associated with preceding
total parasite density and multiplication rates, and negatively
associated with age. The lower gametocyte production among older
children was not explained by antibody responses to blood-stage
antigens, potentially suggesting a role for recently described
immune responses that reduce gametocyte maturation and increase
with age49. Antibody responses to gametocyte/gamete antigens
Pfs48/45 and Pfs230 were associated with reduced infectivity of
successfully produced gametocytes50. Interestingly, infections with
higher clonal complexity resulted in higher mosquito infection
rates, independent of gametocyte densities. Although we observed a
positive association between mosquito infection rates and COI
before in the dry season in Burkina Faso51, other studies found no
association or a higher likelihood of mosquito infection for
monoclonal infections51,52. The low gametocyte production among
incident infections and the rapid abrogation of infection due to
early treatment resulted in marked differences in the likelihood of
mosquitoes becoming infected; only 0.1% of mosquitoes became
infected in incident malaria infections compared to 4.5% in chronic
malaria infections. Whilst this is largely explained by the number of
gametocytes present in the blood at the time of feeding, we also
observed that mosquito infection rates were lower when gameto-
cytes arose early upon incident infections and when gametocyte
donors had malaria symptoms53. The latter is in line with earlier
findings, principally from animal models, on gametocyte-
inactivating activity of inflammatory cytokines and reactive
intermediates54,55. The mechanism by which this might be achieved
and the relative importance for malaria transmission epidemiology
requires further study.
From a public health perspective, our findings indicate that there is
a window of opportunity to prevent onward malaria transmission
from incident infections in semi-immune populations. The abun-
dance, poor detectability, and high infectiousness of asymptomatic
malaria infections suggest that these may be a considerable stumbling
block for malaria elimination. However, if most infections are initially
symptomatic (i.e. if the chronic infections we observed reflect the tail-
end of symptomatic incident infections) enhancing case management
to maximize accessibility of diagnosis and care may abrogate infec-
tions early on and, potentially, before individuals become
infectious56. This is additionally supported by our observations that
incident infections have initially low gametocyte production, are
detectable by rigorous symptom-screening, and that gametocytes are
less likely to achieve mosquito infection when arising early upon
infection or when sampled during a clinical episode. Enhanced case
management may thus reduce the proportion of infections that
proceed to become highly infectious57, in addition to the obvious
clinical benefits of preventing progression to severe disease.
Table 2 Predictors of gametocyte density on day 14.
Covariate Difference in log gametocytes/µl
on day 14a
Adjusted difference in log gametocytes/µl
on day 14b
Incident infection −4.07 [−5.96, −2.18], p < 0.001 −2.52 [−4.55, −0.50], p= 0.016
Female −0.95 [−2.30, 0.40], p= 0.163 –
Age
5–7 0 0
8–10 −1.75 [−3.30, −0.19], p= 0.028 −2.11 [−3.44, −0.77], p= 0.002
Log total parasite density/µl on day 0 (1 unit increase) 0.38 [0.13, 0.63], p= 0.004 0.52 [0.27, 0.77], p < 0.001
Log total parasite density/µl on day 14 (1 unit increase) 0.10 [−0.14, 0.35], p= 0.411 –
Log PMR (1 unit increase) 1.06 [0.05, 2.07], p= 0.040 1.57 [0.08, 3.07], p= 0.040
Hb g/dl on day 14 (1 unit increase) 0.29 [−0.22, 0.81], p= 0.256
Hb genotype p= 0.931
AA 0 –
C 0.31 [−1.36, 1.97] –
S 0.67 [−1.40, 2.73] –
SC 0.52 [−4.85, 5.89] –
COI on day 0 p= 0.239
1–3 0 –
4–6 −1.64 [−3.6, −0.40] –
7–19 −0.86 [−3.01, −1.30] –
Aggregate magnitude of antibody response p= 0.285
Lowest tertile 0 –
Middle tertile 0.40 [−1.33, 2.14] –
Highest tertile 2.27 [−0.57, 5.11] –
Data on day 14 gametocyte density was available for 65 individuals, 52 with chronic infections and 13 with incident infections. Hb genotype: haemoglobin genotype; COI: complexity of infection (number
of parasite clones) on day 0. Aggregate magnitude of antibody response was calculated by ranking each individual according to their combined response to 13 P. falciparum antigens, as described in the
‘Methods’ section.
aAdjusted for whether the infection was incident.
bAdjusted for whether the infection was incident, log total parasite density/µl on day 0, log total parasite multiplication rate (PMR), and age.
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Methods
Study location and screening. The study protocol was approved by the ethical
review boards of the London School of Hygiene and Tropical medicine (LSHTM)
(#9008), the Centre National de Recherche et de Formation sur le Paludisme
(CNRFP) (Deliberation number 2015-3-033) and the Burkina Faso National
Ethical Committee for Health Research.
The study was conducted between June 2015 and December 2017 in Balonghin,
in the health district of Saponé 45 kilometres Southwest of Ouagadougou, Burkina
Faso. Balonghin experiences intense and highly seasonal malaria transmission from
June to October. Children aged ≥5–10 years were screened for enrolment in the
incident infection cohort in 2015 and 2017, and the chronic infection cohort in
2016 and 2017. 7/108 individuals participated in the study in two years, with the
remainder participating in a single year. The purpose of the study and practical
consequences of participation were explained during community meetings;
screening was subsequently conducted at local schools. Individuals whose parent or
guardian provided consent for screening were examined by a GCP-trained
clinician. General criteria for enrolment in either cohort were that individuals were
aged 5–10 years, were willing to provide repeated blood samples over a 6-month
period, and if their caregivers provided informed consent. Exclusion criteria were
complicated symptomatic malaria (defined according to standard World Health
Organization criteria), anaemia (Hb < 8 g/dL), presence of any (chronic) illness that
required immediate clinical care, family history of sudden death or of congenital or
clinical conditions known to prolong QTc interval (e.g. family history of
symptomatic cardiac arrhythmias, clinically relevant bradycardia or severe cardiac
disease), current treatment with drugs which could induce a lengthening of QT
interval, known history of hypersensitivity, allergic or adverse reactions to
piperaquine or other aminoquinolones, severe malnutrition (weight-for-height
being below −3 standard deviation or <70% of median of the NCHS/WHO
normalized reference values), weight below 15 kg, and current or previous
participation in malaria vaccine trials.
Sampling: Incident infection cohort. During screening for the incident infection
cohort, a blood smear was taken for malaria diagnosis. Individuals were eligible for
enrolment if microscopy negative and were treated presumptively with
dihydroartemisinin-piperaquine (Duocotexin®, Beijing Holley-Cotec Pharmaceu-
tical, China, 40 mg dihydroartemisinin and 320 mg piperaquine tetra-phosphate
per tablet) to clear possible sub-patent infections. Following confirmation of
malaria parasite negativity 3 weeks later by P. falciparum 18S nested PCR (nPCR),
individuals were visited weekly for clinical examination and infection status
assessment by HRP2 and pLDH based RDT (RDT, First Response®, Premier
Medical Corporation Ltd., Kachigam, India) microscopy and nPCR. This repeated
sampling continued for up to 6 months (a total of ~25 sampling time points). Upon
detection of an incident infection by nPCR, sampling was intensified to capture the
dynamics of the infection shortly after the first appearance of parasites in the


























































































































Fig. 5 Sexual commitment and gametocyte production. A Gametocyte production (y-axis) is given as the ratio of gametocytes/µL on day 14 to ring-stage
parasites/µL (from sbp1 qRT-PCR) on day 0. Sexual commitment (x-axis) was measured as the ratio of ap2-g mRNA copies to the density of ring-stage
parasites/µL at day 0. Light blue hollow markers= chronic asymptomatic infection, dark blue solid markers= chronic symptomatic infection, light red
hollow markers= incident asymptomatic infection, dark red solid markers= incident symptomatic infection. B Gametocyte production and relative
abundance of gexp-5 transcripts (ratio of gexp-5 copy number to the density of ring-stage parasites/µL at day 0). Colours are as in (A). C Relative ap2-g
abundance for the different cohorts; observations from incident symptomatic and incident asymptomatic infections were combined. This figure is thus
based on 34 observations from combined incident infections, 41 observations from chronic asymptomatic infections, and 10 observations from chronic
symptomatic infections. Box plot boxes span the median, 25th and 75th percentiles; box plot whiskers span the adjacent values with outliers shown as dots.
D Relative gexp-5 abundance and cohort; observations incident symptomatic and incident asymptomatic infections were combined. This figure is thus
based on 22 observations from combined incident infections, 41 observations from chronic asymptomatic infections, and 10 observations from chronic
symptomatic infections. Box plot boxes span the median, 25th and 75th percentiles; box plot whiskers span the adjacent values with outliers shown as dots.
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malaria symptoms that may require treatment. Finger-prick samples were taken on
a daily basis for 7 days. After this first week, sampling was performed weekly until
symptoms occurred (measured temperature ≥37.5 °C or reported fever in last 24 h)
or, if still without symptoms, day 35. Artemether-lumefantrine treatment (AL;
Coartem; Novartis Pharma) was given when symptoms occurred or on day 35,
whichever came first. Upon the first detection of infection, participants were
invited to the insectary for assessment of infectivity; a second feed was performed
on the first day of symptoms or on day 14 following the first detection of parasites
(whichever came first). For individuals who remained asymptomatic throughout
follow-up, a third and final membrane feeding assay was performed on day 35. The
use of nPCR during screening and for infection confirmation was important for
rapid sample turn-around and was performed on-site. Higher sensitivity qPCR
assays (also 18s-based58) were performed later at Radboudumc, and the results of
these assays supersede those of nPCR for all analyses.
Sampling: Chronic infection cohort. During screening for the chronic infection
cohort, individuals were eligible for enrolment if all other eligibility criteria were
met regardless of parasite status. Monthly sampling by nPCR was performed 3–4
times, up to the peak of the transmission season. RDT’s were performed con-
currently with all sampling for nPCR; a positive RDT accompanied by temperature
of ≥37.5 °C prompted immediate treatment with AL as for incident infections.
Individuals were defined as having chronic asymptomatic infection when parasites
were detected by nPCR at two consecutive sampling visits, spaced approxi-
mately 1 month apart, without reported illness, accompanying fever or other
apparent malaria symptoms. These individuals were invited to participate in more
intensive sampling. This intensive sampling phase was identical to the follow-up
described after infection detection in the incident infection cohort, starting
1–2 days after the monthly visit that confirmed eligibility.
Mosquito feeding assays. Membrane feeding was performed as described in
detail in our online protocol to determine infectivity to locally reared female
Anopheles gambiae ss mosquitoes59. Briefly, heparinized blood collected in vacu-
tainers was immediately transferred to a glass mini-feeder and offered to 50–80
mosquitoes. Mosquitoes were kept at 27–29 °C in the insectary on glucose and
dissected 7 days after feeding. Mosquito midguts were examined for the presence of
parasite developmental stages, oocysts, by two independent microscopists.
Parasite detection, quantification and complexity of infection. Thick blood
films were stained with Giemsa and independently read by expert research micro-
scopists over 500 fields for quantification of gametocytes and asexual parasites. The
immediate molecular detection of parasites by qualitative 18S-based nested PCR
(nPCR) was done at CNRFP26, Ouagadougou for the detection of incident and
chronic infections. DNA was extracted from 20 µL of blood collected on filter paper.
DNA extraction was undertaken using Qiagen QIAamp blood extraction kits as per
the manufacturer’s instructions (Cat No./ID: 51306). Confirmatory 18S-based
quantitative real-time polymerase chain reaction (qPCR) was performed at Rad-
boudumc the Netherlands; parasite DNA was extracted from whole blood, with a
detection limit of ~0.01 parasites/μL of blood (equating to 1 parasite in each 100 μL
sample of extracted blood)58. For subsequent analysis, total nucleic acids were
extracted from EDTA blood stored in RNA protect cell reagent (Qiagen, Hilden,
Germany) from 100 μL blood samples stored at CNRFP at −80 °C until shipment on
dry ice. Extraction was done using a MagNAPure LC automated extractor (Total
Nucleic Acid Isolation Kit-High Performance; Roche Applied Science, Indianapolis,
IN, USA). Gametocyte quantification with qRT-PCR amplifying female (Pfs25;
PF3D7_1031000) and male (PfMGET; Pf3D7_1469900) gametocyte mRNA was done
using sex-specific trendlines of cultured gametocytes of the PfDynGFP/P47mCherry
reporter line60. Samples were declared gametocyte negative if the estimated
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Fig. 6 Magnitude of asexual and sexual stage antibody response and parasite multiplication rate. Magnitude of antibody response to specific
P. falciparum antigens is given as the background-adjusted median fluorescence intensity (MFI). Parasite multiplication rate (PMR) is presented as the
geometric mean of each individuals PMR observations, with a dashed line at PMR= 1 (no change in parasite density over 48 h intervals). Plasma samples
were taken from the start of intensive follow-up for both cohorts (incident n= 48, chronic n= 51). Light blue hollow markers= chronic asymptomatic
infection, dark blue solid markers= chronic symptomatic infection, light red hollow markers= incident asymptomatic infection, dark red solid markers=
incident symptomatic infection. Full details of all antigens are in Supplementary Table 1.
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gametocyte density was <0.01/µL (1 gametocyte per 100 µL blood sample); estimates
of male and female gametocytes were adjusted for background signal from asexual
parasites61. qPCR targeting pfap2-g62, gexp-563 and sbp164 was performed and the
ratio of ap2-g or gexp-5 copies to ring-stage parasite density (extrapolated from sbp1
copies) was used as a measure of the proportion of sexually committed ring-stage
parasites45. Primer sequences are provided in Supplementary Table 4.
The complexity of infection (COI) was determined by targeted deep sequencing
of apical membrane antigen 1 (AMA1)65. COI was calculated for samples collected
on day 0, 1, 14 and 35. COI from samples from day 0 or 1 were averaged to provide
a single baseline COI. Human haemoglobin S (HBs) and C (HBc) were genotyped
by DNA amplification by multiplex PCR, followed by allele-specific primer
extension with SNP-specific probes and hybridization to magnetic beads66.
Immuno-assays. IgG antibodies against 14 antigens, 1 targeting pre-erythrocytic
stages (Circumsporozoite protein [CSP]67), 11 targeting the asexual blood stage
(Erythrocyte binding antigen [EBA140, EBA175 and EBA-181]34; Glutamate
rich protein 2 [GLURP-R2]68; Merozoite surface protein 1–19 [MSP1-19]69,
Merozoite surface protein 2 [MSP2-ch150/9 (3D7 family allele)37, and MSP2-
DD2 (FC27 family allele)36]; Apical membrane antigen 1 [AMA1]70, and Reti-
culocyte binding protein homologue [RH2.271, RH4.272, RH5.173]), and 2 tar-
geting sexual stages (Pfs48/45-10c74; Pfs230-CMB75) were quantified at baseline
for each participant using a Luminex MAGPIX© suspension bead array76.
Serological analysis was conducted on serum samples collected at the start of
intensive follow-up (day 0) (incident cohort n= 48, chronic cohort n= 51).
Serum was assayed at a dilution of 1:200. Secondary antibody was an R-
phycoerythrin conjugated goat anti-human IgG (Jackson Immuno Research, PA,
USA; 109-116-098) diluted to 1:200. Data are presented as median fluorescence
intensity (MFI).
Data analysis. All data were recorded on paper forms, double entered in
Microsoft Access 2010 and imported into Stata 15.0 (StataCorp LP, Texas, USA).
Peak parasite densities were compared between the cohorts using Wilcoxon’s
rank-sum test. Changes in parasite densities over time were assessed by mixed-
effects linear regression on log parasite densities, with random effects for parti-
cipants and a linear effect for time. Total parasite multiplication rate (PMR) was
compared between different groups using mixed-effects linear regression on log
PMR, with random effects for participants; PMR itself is based on biological assay
readouts (18s qPCR based parasite densities) and was observed to exceed 32 (the
theoretical maximum PMR in one erythrocytic cycle) for a number of samples.
Correlations were calculated using Spearman’s rank correlation (presented as
Spearman rho). Associations with day 14 gametocyte densities were calculated
using Tobit regression on log-transformed densities, with a cut off at 0.01
gametocytes per microliter. Differences in infectivity to mosquitoes were assessed
by binary regression with a log link. Gametocyte density was accounted for using a
model previously described24. Repeated observations were taken into account
using robust standard errors. Cohort (i.e. incident or chronic infection) was
included in the regression analysis of infectivity along with symptoms (where
symptoms were concurrent or present at any point during follow-up). The rela-
tionship between time to symptoms and grouped antibody response was assessed
with cox regression separately for each cohort. Study participants were divided
into tertiles of response to all pre-erythrocytic and asexual stage antigens based on
the first component of a principal components analysis (PCA) of the log-
transformed MFI. For the analysis of sexual stage antibody response and infec-
tivity, tertiles of response to pre-erythrocytic and asexual antibodies were included
as covariates in the regression model, along with total gametocyte density as
determined at the same time point.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data associated with this study are provided in the online Dryad repository (https://
doi.org/10.5061/dryad.pc866t1n3). Source data are provided with this paper.
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